SRPT (STOCKS)
Sarepta Therapeutics,, Inc. Common Stock
$15.790000
+0.480000 (+3.14%)
Prev close: $15.310000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Douglas S. Ingram
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,665.99M
- Employees
- 1,372
- P/E (TTM)
- -16.36
- P/B (TTM)
- 1.07
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
6
Buy
15
Hold
4
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$2.88 | $1.01 | +1.8683 | +184.67% |
|
Dec 2025 (Q4)
|
$-3.93 | $-1.26 | -2.6746 | -213.05% |
|
Sep 2025 (Q3)
|
$-0.01 | $-0.83 | +0.8217 | +98.80% |
|
Jun 2025 (Q2)
|
$1.89 | $0.77 | +1.1243 | +146.83% |
Financial Statements
| Revenues | $2.18B |
| Benefits Costs and Expenses | $387.63M |
| Costs And Expenses | $1.37B |
| Nonoperating Income/Loss | $65.43M |
| Operating Expenses | $2.20B |
| Selling, General, and Administrative Expenses | $467.04M |
| Other Operating Expenses | $1.73B |
| Operating Income/Loss | -$40.96M |
| Income/Loss From Continuing Operations After Tax | $65.06M |
| Income/Loss From Continuing Operations Before Tax | $745.70M |
| Income Tax Expense/Benefit | -$40.59M |
| Interest Expense, Operating | -$54.63M |
| Net Income/Loss | $65.06M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $65.06M |
| Net Income/Loss Available To Common Stockholders, Basic | $65.06M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.73 |
| Diluted Earnings Per Share | $0.34 |
| Basic Average Shares | 304,805,000 |
| Diluted Average Shares | 330,351,000 |
| Assets | $3.18B |
| Current Assets | $2.31B |
| Inventory | $1.00B |
| Other Current Assets | $1.31B |
| Noncurrent Assets | $869.06M |
| Fixed Assets | $336.24M |
| Other Non-current Assets | $532.82M |
| Liabilities | $1.67B |
| Current Liabilities | $499.16M |
| Accounts Payable | $70.38M |
| Wages | $32.88M |
| Other Current Liabilities | $395.91M |
| Noncurrent Liabilities | $1.17B |
| Long-term Debt | $838.16M |
| Other Non-current Liabilities | $336.51M |
| Equity | $1.51B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.51B |
| Liabilities And Equity | $3.18B |
| Net Cash Flow From Operating Activities | $175.28M |
| Net Cash Flow From Operating Activities, Continuing | $175.28M |
| Net Cash Flow From Investing Activities | $226.43M |
| Net Cash Flow From Investing Activities, Continuing | $226.43M |
| Net Cash Flow From Financing Activities | -$180.57M |
| Net Cash Flow From Financing Activities, Continuing | -$180.57M |
| Net Cash Flow | $221.13M |
| Net Cash Flow, Continuing | $221.13M |
| Comprehensive Income/Loss | $64.66M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$64.53M |
| Other Comprehensive Income/Loss | -$207.00K |